Galectin Thera

GALT NASDAQ
4.000
+0.090
+2.30%
After Hours: 4.100 +0.1 +2.50% 18:02 07/19 EDT
Open
3.910
Prev Close
3.910
High
4.000
Low
3.890
Volume
206.78K
Avg Vol (3M)
379.24K
52 Week High
6.98
52 Week Low
3.170
% Turnover
0.45%
Market Cap
182.38M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Galectin Thera GALT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
MORE >

Recently

Name
Price
%Change